Author

J. Corria-Osorio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

G. Coukos· 2 shared A. Grimm· 1 shared A. Harari· 1 shared A. Orcurto· 1 shared A. Spill· 1 shared B. Navarro· 1 shared B. Seijo· 1 shared C. Andriakopoulou· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Coukos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma

D. Barras, E. Ghisoni, J. Chiffelle, A. Orcurto, J. Dagher, N. Fahr, F. Benedetti, I. Crespo, S. Zimmermann, R. Duran, M. Imbimbo, M. Ochoa De Olza, B. Navarro, K. Homiscko, S. Bobisse, , G. Coukos

This study identifies CD8+ TIL-myeloid cell networks as predictors of response to adoptive TIL therapy in melanoma using single-cell RNA-seq and spatial proteomic analyses.

bioRxiv · Dec 23, 2022 · PreprintImmunology

Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel PD-1+ TOX-indifferent Synthetic Effector State

J. Corria-Osorio, S. J. Carmona, E. Stefanidis, M. J. Andreatta, T. Muller, Y. Ortiz, B. Seijo, W. Castro, C. Jimenez-Luna, L. Scarpellino, C. Ronet, A. Spill, E. Lanitis, S. A. Luther, P. Romero, , G. Coukos

This study shows that orthogonal gene engineering of CD8+ T cells with IL-2 variant, PD1-decoy, and IL-33 enables tumor control through a novel PD-1+ TOX-indifferent synthetic effector state.

bioRxiv · Feb 18, 2022 · PreprintImmunology